AS1069562, the (+)-isomer of indeloxazine, exerts analgesic effects in a rat model of neuropathic pain with unique characteristics in spinal monoamine turnover

Journal of Pharmacology and Experimental Therapeutics

Volumn 348, Issue 3, 2014, Pages 372-382

  Murai, Nobuhito ^a   Aoki, Toshiaki ^a   Tamura, Seiji ^a   Sekizawa, Toshihiro ^a   Kakimoto, Shuichiro ^a   Tsukamoto, Mina ^a   Oe, Tomoya ^a   Enomoto, Ryugo ^a   Hamakawa, Nozomu ^a   Matsuoka, Nobuya ^a  

^a ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

[ 2 [(1H INDEN 7 YLOXY)METHYL]MORPHOLINE MONOBENZENESULFONATE]; AMITRIPTYLINE; DULOXETINE; INDELOXAZINE; NORADRENALIN; SEROTONIN; UNCLASSIFIED DRUG;

ALLODYNIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG EXCRETION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG RESPONSE; HUMAN; HUMAN CELL; HYPERALGESIA; IC 50; MALE; MOUSE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; ROTAROD TEST; SPINAL CORD DORSAL HORN; STOMACH EMPTYING;

AMITRIPTYLINE; ANALGESICS; ANIMALS; BIOGENIC MONOAMINES; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; GASTRIC EMPTYING; HEK293 CELLS; HUMANS; MALE; MORPHOLINES; MOTOR ACTIVITY; NEURALGIA; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; PROTEIN BINDING; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SPINAL CORD; STEREOISOMERISM; THIOPHENES;

EID: 84896723169     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.208686     Document Type: Article

References (30)

1. Bailey JE, Potokar JP, Coupland NJ, and Nutt DJ (1995) The 5-HT3 antagonist ondansetron reduces gastrointestinal side effects induced by a specific serotonin reuptake inhibitor in man. J Psychopharmacol 9:137-141.
2. Bennett GJ and Xie YK (1988) A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man. Pain 33:87-107.
3. Bergeron R and Blier P (1994) Cisapride for the treatment of nausea produced by selective serotonin reuptake inhibitors. Am J Psychiatry 151:1084-1086.
4. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, and Wong DT (2001) Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 25:871-880.
5. Bymaster FP, Lee TC, Knadler MP, Detke MJ, and Iyengar S (2005) The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 11: 1475-1493.
6. Chaplan SR, Bach FW, Pogrel JW, Chung JM, and Yaksh TL (1994) Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 53:55-63.
7. Cheng Y and Prusoff WH (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22:3099-3108.
8. Colpaert FC, Tarayre JP, Koek W, Pauwels PJ, Bardin L, Xu XJ, Wiesenfeld-Hallin Z, Cosi C, Carilla-Durand E, and Assié MB, et al. (2002) Large-amplitude 5-HT1A receptor activation: a new mechanism of profound, central analgesia. Neuropharmacology 43:945-958.
9. de Groote L, Klompmakers AA, Olivier B, and Westenberg HG (2003) Role of extracellular serotonin levels in the effect of 5-HT1B receptor blockade. Psychopharmacology (Berl) 167:153-158.
10. Gaus S, Moriwaki K, Suyama H, Kawamoto M, and Yuge O (2003) Capsaicin treatment inhibits osteopenia and heat hyperalgesia induced by chronic constriction injury to the sciatic nerve in rats. Hiroshima J Med Sci 52:43-51.
11. Hama AT (2002) Capsaicin-sensitive primary afferents mediate responses to cold in rats with a peripheral mononeuropathy. Neuroreport 13:461-464.
12. Harada M, Terai M, Kuroiwa I, and Yamaguchi T (1987) Effects of indeloxazine hydrochloride (YM-08054) on glucose and energy metabolism in mouse brain. Jpn Pharmacol Ther 15:185-192.
13. Hargreaves K, Dubner R, Brown F, Flores C, and Joris J (1988) A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 32: 77-88.
14. Kawamata T, Omote K, Toriyabe M, Kawamata M, and Namiki A (2002) Intracerebroventricular morphine produces antinociception by evoking gammaaminobutyric acid release through activation of 5-hydroxytryptamine 3 receptors in the spinal cord. Anesthesiology 96:1175-1182.
15. Kawasaki-Yatsugi S, Nagakura Y, Ogino S, Sekizawa T, Kiso T, Takahashi M, Ishikawa G, Ito H, and Shimizu Y (2012) Automated measurement of spontaneous pain-associated limb movement and drug efficacy evaluation in a rat model of neuropathic pain. Eur J Pain 16:1426-1436.
16. Meller ST, Gebhart GF, and Maves TJ (1992) Neonatal capsaicin treatment prevents the development of the thermal hyperalgesia produced in a model of neuropathic pain in the rat. Pain 51:317-321.
17. Millan MJ (2002) Descending control of pain. Prog Neurobiol 66:355-474.
18. Mogil JS and Crager SE (2004) What should we be measuring in behavioral studies of chronic pain in animals? Pain 112:12-15.
19. Okamoto K, Imbe H, Tashiro A, Kumabe S, and Senba E (2004) Blockade of peripheral 5HT3 receptor attenuates the formalin-induced nocifensive behavior in persistent temporomandibular joint inflammation of rat. Neurosci Lett 367: 259-263.
20. Pytliak M, Vargová V, Mechírová V, and Felsöci M (2011) Serotonin receptors-from molecular biology to clinical applications. Physiol Res 60:15-25.
21. Rosenzweig-Lipson S, Beyer CE, Hughes ZA, Khawaja X, Rajarao SJ, Malberg JE, Rahman Z, Ring RH, and Schechter LE (2007) Differentiating antidepressants of the future: efficacy and safety. Pharmacol Ther 113:134-153.
22. Shimizu-Sasamata M, Yamamoto M, and Harada M (1993) Cerebral activating properties of indeloxazine HCl and its optical isomers. Pharmacol Biochem Behav 45:335-341.
23. Shimizu-Sasamata M, Yamamoto M, Okada M, Yamaguchi T, and Tamura A (1991) Effects of indeloxazine hydrochloride on behavioral and biochemical changes in the chronic phase of focal cerebral ischemia in rats. Arch Int Pharmacodyn Ther 314: 74-89.
24. Suzuki R, Rygh LJ, and Dickenson AH (2004) Bad news from the brain: descending 5-HT pathways that control spinal pain processing. Trends Pharmacol Sci 25: 613-617.
25. Thor KB, Kirby M, and Viktrup L (2007) Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: scientific basis for overlapping clinical efficacy from a single drug, duloxetine. Int J Clin Pract 61:1349-1355.
26. Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, Hansson P, Hughes R, Nurmikko T, and Serra J (2008) Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurology 70:1630-1635.
27. Yamaguchi T, Ohyama M, Suzuki M, Ozawa Y, Hatanaka K, Hidaka K, and Yamamoto M (1998) Neurochemical and behavioral characterization of potential antidepressant properties of indeloxazine hydrochloride. Neuropharmacology 37:1169-1176.
28. Yamaguchi T, Suzuki M, and Yamamoto M (1997) Facilitation of acetylcholine release in rat frontal cortex by indeloxazine hydrochloride: involvement of endogenous serotonin and 5-HT4 receptors. Naunyn Schmiedebergs Arch Pharmacol 356: 712-720.
29. Yamamoto M (1990) Pharmacological and biochemical properties of indeloxazine hydrochloride, a new cerebral activator. Brain Dysfunct 3:130-147.
30. Yamamoto M, Ooyama M, Ozawa Y, Okada M, Tada S, Yamaguchi T, and Endo H (1993) Effects of indeloxazine hydrochloride, a cerebral activator, on passive avoidance learning impaired by disruption of cholinergic transmission in rats. Neuropharmacology 32:695-701.